These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37354089)

  • 1. Inhalable siRNA Nanoparticles for Enhanced Tumor-Targeting Treatment of
    Zhao G; Ho W; Chu J; Xiong X; Hu B; Boakye-Yiadom KO; Xu X; Zhang XQ
    ACS Appl Mater Interfaces; 2023 Jul; 15(26):31273-31284. PubMed ID: 37354089
    [No Abstract]   [Full Text] [Related]  

  • 2. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
    Gu L; Deng ZJ; Roy S; Hammond PT
    Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
    [No Abstract]   [Full Text] [Related]  

  • 3. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
    Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
    Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
    Mehta A; Dalle Vedove E; Isert L; Merkel OM
    Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
    Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
    Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
    Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
    Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.
    Sreedurgalakshmi K; Srikar R; Harikrishnan K; Srinivasan L; Rajkumari R
    Technol Cancer Res Treat; 2021; 20():15330338211041453. PubMed ID: 34542333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
    Shimamura T; Chen Z; Soucheray M; Carretero J; Kikuchi E; Tchaicha JH; Gao Y; Cheng KA; Cohoon TJ; Qi J; Akbay E; Kimmelman AC; Kung AL; Bradner JE; Wong KK
    Clin Cancer Res; 2013 Nov; 19(22):6183-92. PubMed ID: 24045185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small RNA combination therapy for lung cancer.
    Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery.
    Mao CQ; Xiong MH; Liu Y; Shen S; Du XJ; Yang XZ; Dou S; Zhang PZ; Wang J
    Mol Ther; 2014 May; 22(5):964-73. PubMed ID: 24496383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status and outlook of medical treatment for
    Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
    Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
    Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
    Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
    Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
    Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
    Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS-Mutant non-small cell lung cancer: From biology to therapy.
    Ferrer I; Zugazagoitia J; Herbertz S; John W; Paz-Ares L; Schmid-Bindert G
    Lung Cancer; 2018 Oct; 124():53-64. PubMed ID: 30268480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.
    Niloy MS; Shakil MS; Alif MMH; Rosengren RJ
    Curr Med Chem; 2021; 28(39):8098-8115. PubMed ID: 33645474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Fukuda K; Otani S; Takeuchi S; Arai S; Nanjo S; Tanimoto A; Nishiyama A; Naoki K; Yano S
    Cancer Sci; 2021 Sep; 112(9):3784-3795. PubMed ID: 34145930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer.
    Tang KJ; Constanzo JD; Venkateswaran N; Melegari M; Ilcheva M; Morales JC; Skoulidis F; Heymach JV; Boothman DA; Scaglioni PP
    Clin Cancer Res; 2016 Dec; 22(23):5851-5863. PubMed ID: 27220963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.